- Home
- HALO
as 04-18-2025 1:37pm EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 7.4B | IPO Year: | N/A |
| Target Price: | $61.63 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.43 | EPS Growth: | 63.33 |
| 52 Week Low/High: | $37.73 - $66.00 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,015,324,000 | Revenue Growth: | 22.44% |
| Revenue Growth (this year): | 20.06% | Revenue Growth (next year): | 24.04% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Henderson Jeffrey William | HALO | Director | Apr 1 '25 | Sell | $64.05 | 503 | $32,217.15 | 33,108 | |
| Henderson Jeffrey William | HALO | Director | Mar 3 '25 | Sell | $58.53 | 5,000 | $293,458.31 | 33,108 | |
| LaBarre Michael J. | HALO | SVP, CHIEF TECHNICAL OFFICER | Feb 25 '25 | Sell | $58.40 | 21,697 | $1,260,680.74 | 173,856 | |
| Henderson Jeffrey William | HALO | Director | Feb 3 '25 | Sell | $56.17 | 5,000 | $281,516.80 | 33,108 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity
Argus Research
4 days ago
HALO: Raising target price to $67.00
Investor's Business Daily
8 days ago
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market
MT Newswires
8 days ago
Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx
PR Newswire
9 days ago
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
MT Newswires
10 days ago
Halozyme Says European Commission Approves Darzalex Co-Formulated With Enhanze to Treat Multiple Myeloma
PR Newswire
10 days ago
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
Argus Research
11 days ago
HALO: Rating increased to a BUY
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.